Oculis to present Privosegtor biomarker data at MS conference
Tweet Send to a Friend
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) announced it will present biomarker analyses from its Phase 2 ACUITY trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




